Navigation Links
R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
Date:7/23/2009

SOUTH SAN FRANCISCO, Calif., July 23 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that in the TASKi3 Phase 2b clinical trial in rheumatoid arthritis (RA) patients who had failed to respond to at least one biologic treatment, the group treated with R788 (fostamatinib disodium) did not report significantly higher ACR 20, ACR 50, ACR 70 and DAS28 response rates than the placebo group at three months, and therefore, the trial failed to meet its efficacy endpoints. The objective components (CRP and ESR)* of these ACR scores did show a statistically significant difference; however, the subjective reported response rate components did not as compared to placebo. Although the ACR scores for the R788 group were within the expected range in this patient population, the reported placebo response rates were considerably higher than seen in any other previous study of RA biologic failure patients and rose unaccountably between week 6 (at which point the reported response rates between R788 and placebo were significantly different) and month 3 (when such reported response rates were no longer significantly different).

TASKi3 was the first clinical trial evaluating R788 in which anatomical changes in the patients' wrist and hands were evaluated using Magnetic Resonance Imaging (MRI) and scored using the RAMRIS (Rheumatoid Arthritis Magnetic Resonance Imaging Scoring) system. Those results showed improvements in the treated group versus the placebo group in the Synovitis and Osteitis scores, while the Erosion scores, known to be the slowest to change, showed no significant effect at three months. The most frequent adverse events were as expected from the earlier TASKi trials and appear to be manageable.

Rigel will host a conference call today at 7PM EDT/ 4PM PDT
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)...  Following a bipartisan vote in the House ... the Medicare DMEPOS Competitive Bidding Improvement Act of ... released a statement praising the Committee,s work and ... "Today,s mark-up of the Competitive Bidding ... Committee is a critical step forward for this ...
(Date:2/27/2015)... and HOUSTON, TX , Feb. 27, ... (TSX-V: EPI) and Bloom Burton & Co. Ltd. ("Bloom ... contractual lock-up (the "Lock-Up") 2,353,130 common shares of the ... originally subject to the Lock-Up. Of the Common Shares ... trading immediately upon release from the Lock-Up while the ...
(Date:2/27/2015)... , Feb. 27, 2015   Synageva BioPharma Corp. ... biopharmaceutical company developing therapeutic products for rare diseases, ... the European Organisation for Rare Diseases™ (EURORDIS™), The ... in observing Rare Disease Day. On ... organizations, industry, and other participants conduct special events ...
Breaking Medicine Technology:Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
... 2011 GHX CEO Bruce Johnson ... an audience of over 600 healthcare business leaders this morning ... sustainable healthcare system at the opening keynote of the GHX ... is focused on the future of the healthcare supply chain ...
... WINOOSKI, Vt., April 19, 2011 Physician,s Computer Company ... ready to begin full production of the updated 5010 ... is frustrated by a lack of readiness among its ... January by the Health Information and Management Systems Society ...
Cached Medicine Technology:Getting Healthcare Reform Done with the Entire Supply Chain 2Getting Healthcare Reform Done with the Entire Supply Chain 3Getting Healthcare Reform Done with the Entire Supply Chain 4PCC Frustrated with Payers' Lack of 5010 Readiness 2
(Date:3/1/2015)... 01, 2015 Theme and plugin developers ... transition pack for Final Cut Pro X entitled ... transitions to any FCPX editors project.” Said Christiana Austin, ... the tools needed to easily drag and drop their ... gets many different controls over the parameters of this ...
(Date:2/28/2015)... March 01, 2015 Heart diseases are ... 10 percent of urban adult population and 5 percent ... heart diseases and 20-30 percent of them require specialized ... ailments and coronary vascular diseases (CVD). , A division ... new market research report titled “Indian Coronary Stent Market ...
(Date:2/28/2015)... The Heart Fit Clinic started doing External ... machine. The Heart Fit Clinic is also selling the ... model. The goal is to scale the business to ... buy External Counterpulsation machines can be difficult ... this process and achieve the desired results. , ...
(Date:2/28/2015)... Vancouver personal injury lawyers at Jiwa Law Corporation recently ... limits. They stated that in many cases, missing an important ... it. Many a time, delays in making an injury claim ... law. As a result, experts at Jiwa Law Corporation suggest ... personal injury lawyer in order to know more about their ...
(Date:2/28/2015)... February 28, 2015 The Mesothelioma ... annual awards at the International Symposium on Malignant Mesothelioma ... held at the Hyatt Regency Bethesda in Bethesda, Maryland. ... dedicated work and commitment to the mission to cure ... Award will be presented to Miriam Ratner. Miriam runs ...
Breaking Medicine News(10 mins):Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4
... will able to uncover the fate of the lost colony ... more than 100 people settled on the Roanoke Island ... deeds and historical narratives have gathered around 168 surnames that ... of the English trying to colonize the new world. ...
... with bird flu in Indonesia appear healthy, making it difficult ... for humans, an official said Monday. ,Indonesia, ... has been struggling to control H5N1 outbreaks across its vast ... found that chickens infected by bird flu have not been ...
... majority of Britain's casinos on Monday lost its ... the country's gambling industry. The British Casino ... that Labour's policy to create 17 new casinos, ... existing gaming establishments with "blatant unfairness." ...
... Stress not only makes your present life miserable, it drags ... Alzheimers, say researchers. ,Researchers from Rush University ... are anxious or depressed are 40 times more likely to ... is often a transitional stage between normal aging and dementia, ...
... Japanese scientists have created a vaccine for cholera that can ... of the University of Tokyo and his colleagues inserted the ... into a rice plant, whose genome has recently been mapped. ... were fed to mice they provoked immunity from the diarrhea-causing ...
... might be able to conceive at an age generally thought to ... expected to come up in the next decade or so. ... be developed into a pill or an injection to extend the ... a fertility revolution enabling women to wait longer to have a ...
Cached Medicine News:Health News:DNA Link to a Lost Colony 2Health News:Stress- Harms Now And Later 2Health News:Vaccines On Your Plate 2
... Viral RNA Mini Kit allows ... from cell-free fluid samples. Examples ... can be isolated with this ... limited to, RNA from hepatitis ...
... LABOTECH is an automated microplate ... immunoenzymatic microplate techniques. Open architecture ... to many manufacturers' microplate assays ... traditional R.I.A. and I.F.A. methods ...
... AP-22 Micro Plate Processor is ... Automated Microplate Analyzer. It has been ... assigned area can be customised according ... Micro Plate Processor is able to ...
The GEM OPL CO-Oximeter provides comprehensive oxygenation status in an easy-to-use, portable manner. The GEM OPL is the ideal solution for laboratory or point-of-care CO-Oximetry testing....
Medicine Products: